SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-015763
Filing Date
2023-05-04
Accepted
2023-05-04 16:19:34
Documents
77
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20230331.htm   iXBRL 10-Q 1359530
2 EX-31.1 ex-311q12023.htm EX-31.1 9357
3 EX-31.2 ex-312q12023.htm EX-31.2 9347
4 EX-32.1 ex-321q12023.htm EX-32.1 5550
10 xfor-20230331_g1.jpg GRAPHIC 469223
  Complete submission text file 0001628280-23-015763.txt   7256056

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20230331.xsd EX-101.SCH 49805
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20230331_cal.xml EX-101.CAL 60663
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20230331_def.xml EX-101.DEF 178490
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20230331_lab.xml EX-101.LAB 526146
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20230331_pre.xml EX-101.PRE 349053
71 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20230331_htm.xml XML 920117
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 23889054
SIC: 2836 Biological Products, (No Diagnostic Substances)